All News
ICYMI: Towards Personalised Care in Rheumatoid Arthritis
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients.
Read ArticleICYMI: Issues in AxSpA: Treatment Intensification, Pregnancy
A lot of interesting studies will be presented at the poster sessions on Sunday, November 12 and some of them address practical real-world issues such as treatment intensification and the impact of pregnancy on axSpA imaging.
Read ArticleCan Rheumatologists Accurately Diagnose axSpA in Patients with Chronic Back Pain?
Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature.
Read ArticleRheumatology Roundup - ACR 2023
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
Read ArticleHow early is early in psoriatic arthritis?
Guidelines (ACR/EULAR/GRAPPA) for the management of psoriatic arthritis (PsA) recommend the early referral of patients with the suspected condition for early assessment and treatment.
Read ArticleCanadian Consensus on MSK Ultrasound
Dr. Jack Cush discusses abstract 0726 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Read ArticleIssues in AxSpA: Treatment Intensification, Pregnancy
A lot of interesting studies will be presented at the poster sessions on Sunday, November 12 and some of them address practical real-world issues such as treatment intensification and the impact of pregnancy on axSpA imaging.
Read ArticleTowards Personalised Care in Rheumatoid Arthritis
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients.
Read ArticleACR Convergence Preview (11.10.2023)
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
Read Article